ea0014oc4.4 | Neuroendocriology basis | ECE2007
Filopanti Marcello
, Barbieri Anna Maria
, Angioni Rita
, Lania Andrea
, Mantovani Giovanna
, Spada Anna
, Beck-Peccoz Paolo
Dopamine agonist cabergoline (CB) is the first-choice treatment in prolactin-secreting adenomas (PRL-omas). It is effective in reducing PRL secretion and tumour size in about 90% of patients by binding dopamine D2 receptor (DRD2). Although no mutations in DRD2 were found, it has been reported that several polymorphisms of this locus associate with alcoholism and schizophrenia, diseases in which dopaminergic system plays an important role. To assess the possible asso...